Voyager-V1 is under clinical development by Vyriad and currently in Phase I for Adenocarcinoma. According to GlobalData, Phase I drugs for Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Voyager-V1 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Voyager-V1 overview

Voyager-V1 is under development for the treatment of metastatic melanoma and endometrial cancer and for relapsed and refractory hematological malignancies, solid tumors including metastatic colorectal cancer, pheochromocytoma, neuroendocrine tumor, endometrioid adenocarcinoma, non-small cell lung cancer, neuroendocrine carcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, multiple myeloma, relapsed AML, non-Hodgkin lymphoma, T-cell lymphoma such as peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, myelodysplastic syndrome, cutaneous TCL (CTCL) of mycosis fungoides (MF). The therapeutic candidate is administered by the intravenous and intratumoral route of administration. The drug candidate, vesicular stomatitis virus (VSV)-interferon beta (IFNb)-sodium iodide symporter (NIS) is an oncolytic VSV encoding IFNb and the NIS reporter. The therapeutic candidate is developed based on VSV (VSV- IFNb-NIS) technology platform. The drug candidate acts by targeting interferon beta (IFNb) and SLC5A5.

It was also under development for metastatic hepatocullular carcinoma, breast, ovarian cancer, hepatocellular carcinoma and head and neck squamous cell carcinoma.

Vyriad overview

Vyriad is a clinical-stage biotechnology company that develops oncolytic virus therapies for the treatment of cancers. It develops drugs using two oncolytic virus platforms that include vesicular stomatitis virus (VSV) and measles virus (MV-NIS). The company’s pipeline products include Voyager-V1 + cemiplimab treats multiple cancers; Voyager-V1 + pembrolizumab for non-small cell lung cancer, head and neck cancer; MV-NIS monotherapy targets bladder cancer; Voyager-V1 monotherapy for solid tumors. Vyriad’s investigator-sponsored clinical studies include Voyager-V1 +/- ruxolitinib for multiple myeloma, T cell lymphoma; MV-NIS monotherapy targets medulloblastoma and recurrent atypical teratoid rhabdoid tumor (ATRT); Voyager-V1 +/- ruxolitinib for endometrial cancer. Vyriad is headquartered in Rochester, Minnesota, the US.

For a complete picture of Voyager-V1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.